Crucell and NIH sign EUR 21.4 million Ebola Vaccine Manufacturing Contract
15-Apr-2005
Under the terms of the contract, Crucell will manufacture up to ten batches of clinical material of the PER.C6®-based Ebola vaccine in its own manufacturing facility. These materials will be used for Phase I and early Phase II clinical studies in humans. Crucell will receive up to EUR 21.4 million (US$ 27.6 million) from the VRC for the manufacturing of these clinical lots.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.